Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Aug 9;16(4):507–517. doi: 10.1007/s11684-022-0952-z

Unusual global outbreak of monkeypox: what should we do?

Miaojin Zhu 1,#, Jia Ji 1,#, Danrong Shi 1,#, Xiangyun Lu 1, Baohong Wang 1,2, Nanping Wu 1,2, Jie Wu 1,2,✉, Hangping Yao 1,2,✉, Lanjuan Li 1,2,✉
PMCID: PMC9362077  PMID: 35943705

Abstract

Recently, monkeypox has become a global concern amid the ongoing COVID-19 pandemic. Monkeypox is an acute rash zoonosis caused by the monkeypox virus, which was previously concentrated in Africa. The re-emergence of this pathogen seems unusual on account of outbreaks in multiple nonendemic countries and the incline to spread from person to person. We need to revisit this virus to prevent the epidemic from getting worse. In this review, we comprehensively summarize studies on monkeypox, including its epidemiology, biological characteristics, pathogenesis, and clinical characteristics, as well as therapeutics and vaccines, highlighting its unusual outbreak attributed to the transformation of transmission. We also analyze the present situation and put forward countermeasures from both clinical and scientific research to address it.

Keywords: monkeypox, poxviruses, vaccine, infectious diseases

Acknowledgements

This work was supported by the National Key Research & Development Program of China (No. 2021YFC2301204), Zhejiang Provincial Key Research & Development Program of China (No. 2021C03043), and Research Project of Jinan Microecological Biomedicine Shandong Laboratory.

Footnotes

Compliance with ethics guidelines

Miaojin Zhu, Jia Ji, Danrong Shi, Xiangyun Lu, Baohong Wang, Nanping Wu, Jie Wu, Hangping Yao, and Lanjuan Li declare no competing financial interests. This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Miaojin Zhu, Jia Ji, and Danrong Shi contributed equally to this study.

Contributor Information

Jie Wu, Email: zjwujie@zju.edu.cn.

Hangping Yao, Email: yaohangping@zju.edu.cn.

Lanjuan Li, Email: ljli@zju.edu.cn.

References

  • 1.CDC. 2022 Monkeypox Outbreak Global Map. 2022. Available at the US CDC website (accessed July 8, 2022)
  • 2.Frey SE, Belshe RB. Poxvirus zoonoses—putting pocks into context. N Engl J Med. 2004;350(4):324–327. doi: 10.1056/NEJMp038208. [DOI] [PubMed] [Google Scholar]
  • 3.Henderson DA. The looming threat of bioterrorism. Science. 1999;283(5406):1279–1282. doi: 10.1126/science.283.5406.1279. [DOI] [PubMed] [Google Scholar]
  • 4.Weiss MM, Weiss PD, Mathisen G, Guze P. Rethinking smallpox. Clin Infect Dis. 2004;39(11):1668–1673. doi: 10.1086/425745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bozzette SA, Boer R, Bhatnagar V, Brower JL, Keeler EB, Morton SC, Stoto MA. A model for a smallpox-vaccination policy. N Engl J Med. 2003;348(5):416–425. doi: 10.1056/NEJMsa025075. [DOI] [PubMed] [Google Scholar]
  • 6.World Health Assembly . Report of the global commission for the certification of smallpox eradication. Geneva: World Health Organization; 1980. [Google Scholar]
  • 7.Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593–597. [PMC free article] [PubMed] [Google Scholar]
  • 8.Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988;17(3):643–650. doi: 10.1093/ije/17.3.643. [DOI] [PubMed] [Google Scholar]
  • 9.Grant R, Nguyen LL, Breban R. Modelling human-to-human transmission of monkeypox. Bull World Health Organ. 2020;98(9):638–640. doi: 10.2471/BLT.19.242347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med. 2022;29(3):taac037. doi: 10.1093/jtm/taac037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Magnus P, Andersen EK, Petersen KB, Birch-Andersen A. A poxlike disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 1959;46(2):156–176. doi: 10.1111/j.1699-0463.1959.tb00328.x. [DOI] [Google Scholar]
  • 12.Sklenovská N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health. 2018;6:241. doi: 10.3389/fpubh.2018.00241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Reynolds MG, Carroll DS, Karem KL. Factors affecting the likelihood of monkeypox’s emergence and spread in the post-smallpox era. Curr Opin Virol. 2012;2(3):335–343. doi: 10.1016/j.coviro.2012.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Schneider KA, Eichner M. Does it matter who is spreading monkeypox? Lancet Infect Dis 2022; [Epub ahead of print] doi:10.1016/S1473-3099(22)00431-5 [DOI] [PMC free article] [PubMed]
  • 15.Wenner HA, Macasaet FD, Kamitsuka PS, Kidd P. Monkey pox. I. Clinical, virologic and immunologic studies. Am J Epidemiol. 1968;87(3):551–566. doi: 10.1093/oxfordjournals.aje.a120846. [DOI] [PubMed] [Google Scholar]
  • 16.Prier JE, Sauer RM. A pox disease of monkeys. Ann N Y Acad Sci. 1960;85(3):951–959. doi: 10.1111/j.1749-6632.1960.tb50015.x. [DOI] [PubMed] [Google Scholar]
  • 17.Nakoune E, Lampaert E, Ndjapou SG, Janssens C, Zuniga I, Van Herp M, Fongbia JP, Koyazegbe TD, Selekon B, Komoyo GF, Garba-Ouangole SM, Manengu C, Manuguerra JC, Kazanji M, Gessain A, Berthet N. A nosocomial outbreak of human monkeypox in the Central African Republic. Open Forum Infect Dis. 2017;4(4):ofx168. doi: 10.1093/ofid/ofx168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Marennikova SS, Seluhina EM, Mal’ceva NN, Cimiskjan KL, Macevic GR. Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. Bull World Health Organ. 1972;46(5):599–611. [PMC free article] [PubMed] [Google Scholar]
  • 19.Sklenovská N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health. 2018;6:241. doi: 10.3389/fpubh.2018.00241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, Djingarey MH, Olson V, Damon IK, Khalakdina A. Emergence of monkeypox–West and Central Africa, 1970–2017. MMWR Morb Mortal Wkly Rep. 2018;67(10):306–310. doi: 10.15585/mmwr.mm6710a5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Quiner CA, Moses C, Monroe BP, Nakazawa Y, Doty JB, Hughes CM, McCollum AM, Ibata S, Malekani J, Okitolonda E, Carroll DS, Reynolds MG. Presumptive risk factors for monkeypox in rural communities in the Democratic Republic of the Congo. PLoS One. 2017;12(2):e0168664. doi: 10.1371/journal.pone.0168664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The changing epidemiology of human monkeypox-a potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141. doi: 10.1371/journal.pntd.0010141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Adegboye OA, Eugenia Castellanos M, Alele FO, Pak A, Ezechukwu HC, Hou K, Emeto TI. Travel-related monkeypox outbreaks in the era of COVID-19 pandemic: are we prepared? Viruses. 2022;14(6):1283. doi: 10.3390/v14061283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hughes AL, Irausquin S, Friedman R. The evolutionary biology of poxviruses. Infect Genet Evol. 2010;10(1):50–59. doi: 10.1016/j.meegid.2009.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zheng L, Meng J, Lin M, Lv R, Cheng H, Zou L, Sun J, Li L, Ren R, Wang S. Structure prediction of the entire proteome of monkeypox variants. Acta Materia Medica. 2022;1(2):260–264. doi: 10.15212/AMM-2022-0017. [DOI] [Google Scholar]
  • 26.Vandenbogaert M, Kwasiborski A, Gonofio E, Descorps-Declère S, Selekon B, Nkili Meyong AA, Ouilibona RS, Gessain A, Manuguerra JC, Caro V, Nakoune E, Berthet N. Nanopore sequencing of a monkeypox virus strain isolated from a pustular lesion in the Central African Republic. Sci Rep. 2022;12(1):10768. doi: 10.1038/s41598-022-15073-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, Ryazankina OI, Petrov NA, Babkin IV, Uvarova EA, Sandakhchiev LS, Sisler JR, Esposito JJ, Damon IK, Jahrling PB, Moss B. Analysis of the monkeypox virus genome. Virology. 2002;297(2):172–194. doi: 10.1006/viro.2002.1446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Babkin IV, Babkina IN, Tikunova NV. An update of orthopoxvirus molecular evolution. Viruses. 2022;14(2):388. doi: 10.3390/v14020388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, Mixão V, Ferreira R, Santos D, Duarte S, Vieira L, Borrego MJ, Núncio S, de Carvalho IL, Pelerito A, Cordeiro R, Gomes JP. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med 2022; [Epub ahead of print] doi:10.1038/s41591-022-01907-y [DOI] [PMC free article] [PubMed]
  • 30.Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2007;2(1):17–34. doi: 10.2217/17460913.2.1.17. [DOI] [PubMed] [Google Scholar]
  • 31.Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. 2005;41(12):1765–1771. doi: 10.1086/498155. [DOI] [PubMed] [Google Scholar]
  • 32.Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, Muyembe JJ. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA. 2010;107(37):16262–16267. doi: 10.1073/pnas.1005769107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hutson CL, Olson VA, Carroll DS, Abel JA, Hughes CM, Braden ZH, Weiss S, Self J, Osorio JE, Hudson PN, Dillon M, Karem KL, Damon IK, Regnery RL. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. Gen Virol. 2009;90(2):323–333. doi: 10.1099/vir.0.005108-0. [DOI] [PubMed] [Google Scholar]
  • 34.Rao AK, Schulte J, Chen TH, Hughes CM, Davidson W, Neff JM, Markarian M, Delea KC, Wada S, Liddell A, Alexander S, Sunshine B, Huang P, Honza HT, Rey A, Monroe B, Doty J, Christensen B, Delaney L, Massey J, Waltenburg M, Schrodt CA, Kuhar D, Satheshkumar PS, Kondas A, Li Y, Wilkins K, Sage KM, Yu Y, Yu P, Feldpausch A, McQuiston J, Damon IK, McCollum AM, July 2021 Monkeypox Response Team Monkeypox in a traveler returning from Nigeria–Dallas, Texas, July 2021. MMWR Morb Mortal Wkly Rep. 2022;71(14):509–516. doi: 10.15585/mmwr.mm7114a1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kisalu NK, Mokili JL. Toward understanding the outcomes of monkeypox infection in human pregnancy. J Infect Dis. 2017;216(7):795–797. doi: 10.1093/infdis/jix342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Silva NIO, de Oliveira JS, Kroon EG, Trindade GS, Drumond BP. Here, there, and everywhere: the wide host range and geographic distribution of zoonotic orthopoxviruses. Viruses. 2020;13(1):43. doi: 10.3390/v13010043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bonilla-Aldana DK, Rodriguez-Morales AJ. Is monkeypox another reemerging viral zoonosis with many animal hosts yet to be defined? Vet Q. 2022;42(1):148–150. doi: 10.1080/01652176.2022.2088881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kupferschmidt K. Why monkeypox is mostly hitting men who have sex with men. Science. 2022;376(6600):1364–1365. doi: 10.1126/science.add5966. [DOI] [PubMed] [Google Scholar]
  • 39.Heskin J, Belfield A, Milne C, Brown N, Walters Y, Scott C, Bracchi M, Moore LS, Mughal N, Rampling T, Winston A, Nelson M, Duncan S, Jones R, Price DA, Mora-Peris B. Transmission of monkeypox virus through sexual contact — a novel route of infection. J Infect 2022; [Epub ahead of print] doi:10.1016/j.jinf.2022.05.028 [DOI] [PMC free article] [PubMed]
  • 40.Bellinato F, Gisondi P, Girolomoni G. Monkeypox virus infection: what dermatologist needs to know? J Eur Acad Dermatol Venereol 2022; [Epub ahead of print] doi:10.1111/jdv.18299 [DOI] [PubMed]
  • 41.Kabuga AI, El Zowalaty ME. A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria. J Med Virol. 2019;91(4):533–540. doi: 10.1002/jmv.25348. [DOI] [PubMed] [Google Scholar]
  • 42.Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, Gedela K, Scott C, Patel S, Gohil J, Nugent D, Suchak T, Dickinson M, Feeney M, Mora-Peris B, Stegmann K, Plaha K, Davies G, Moore LSP, Mughal N, Asboe D, Boffito M, Jones R, Whitlock G. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis 2022; [Epub ahead of print] doi:10.1016/S1473-3099(22)00411-X [DOI] [PMC free article] [PubMed]
  • 43.Fenner F. The pathogenesis of the acute exanthems; an interpretation based on experimental investigations with mousepox; infectious ectromelia of mice. Lancet. 1948;252(6537):915–920. doi: 10.1016/S0140-6736(48)91599-2. [DOI] [PubMed] [Google Scholar]
  • 44.Shepardson KM, Schwarz B, Larson K, Morton RV, Avera J, McCoy K, Caffrey A, Harmsen A, Douglas T, Rynda-Apple A. Induction of antiviral immune response through recognition of the repeating subunit pattern of viral capsids is Toll-like receptor 2 dependent. MBio. 2017;8(6):e01356–e01317. doi: 10.1128/mBio.01356-17. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 45.Yu H, Bruneau RC, Brennan G, Rothenburg S. Battle royale: innate recognition of poxviruses and viral immune evasion. Biomedicines. 2021;9(7):765. doi: 10.3390/biomedicines9070765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hammarlund E, Dasgupta A, Pinilla C, Norori P, Früh K, Slifka MK. Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. Proc Natl Acad Sci USA. 2008;105(38):14567–14572. doi: 10.1073/pnas.0800589105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Kindrachuk J, Arsenault R, Kusalik A, Kindrachuk KN, Trost B, Napper S, Jahrling PB, Blaney JE. Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus. Mol Cell Proteomics. 2012;11(6):M111.015701. doi: 10.1074/mcp.M111.015701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Estep RD, Messaoudi I, O’Connor MA, Li H, Sprague J, Barron A, Engelmann F, Yen B, Powers MF, Jones JM, Robinson BA, Orzechowska BU, Manoharan M, Legasse A, Planer S, Wilk J, Axthelm MK, Wong SW. Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol. 2011;85(18):9527–9542. doi: 10.1128/JVI.00199-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, Op de Coul E, Brandwagt D, van Cleef B, van Rijckevorsel G, Swaan C, van den Hof S, Wallinga J. Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Euro Surveill. 2022;27(24):2200448. doi: 10.2807/1560-7917.ES.2022.27.24.2200448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin North Am. 2019;33(4):1027–1043. doi: 10.1016/j.idc.2019.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM; NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022; [Epub ahead of print] doi:10.1016/S1473-3099(22)00228-6 [DOI] [PMC free article] [PubMed]
  • 52.McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014;58(2):260–267. doi: 10.1093/cid/cit703. [DOI] [PubMed] [Google Scholar]
  • 53.Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, Paran N, Politi B, Tamir H, Israely T, Weiss S, Beth-Din A, Shifman O, Israeli O, Yitzhaki S, Shapira SC, Melamed S, Schwartz E. Diagnosis of imported monkeypox, Israel, 2018. Emerg Infect Dis. 2019;25(5):980–983. doi: 10.3201/eid2505.190076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, Mamadu I, Akinpelu A, Ahmad A, Burga J, Ndoreraho A, Nkunzimana E, Manneh L, Mohammed A, Adeoye O, Tom-Aba D, Silenou B, Ipadeola O, Saleh M, Adeyemo A, Nwadiutor I, Aworabhi N, Uke P, John D, Wakama P, Reynolds M, Mauldin MR, Doty J, Wilkins K, Musa J, Khalakdina A, Adedeji A, Mba N, Ojo O, Krause G, Ihekweazu C, CDC Monkeypox Outbreak Team Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19(8):872–879. doi: 10.1016/S1473-3099(19)30294-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Macneil A, Reynolds MG, Braden Z, Carroll DS, Bostik V, Karem K, Smith SK, Davidson W, Li Y, Moundeli A, Mombouli JV, Jumaan AO, Schmid DS, Regnery RL, Damon IK. Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity. Clin Infect Dis. 2009;48(1):e6–e8. doi: 10.1086/595552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Patrocinio-Jesus R, Peruzzu F. Monkeypox genital lesions. N Engl J Med. 2022;387(1):66. doi: 10.1056/NEJMicm2206893. [DOI] [PubMed] [Google Scholar]
  • 57.Walter K, Malani PN. What is monkeypox? JAMA 2022; [Epub ahead of print] doi:10.1001/jama.2022.10259 [DOI] [PubMed]
  • 58.Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B, Metcalfe MG, Likafi T, Lushima RS, Kabamba J, Nguete B, Malekani J, Pukuta E, Karhemere S, Muyembe Tamfum JJ, Okitolonda Wemakoy E, Reynolds MG, Schmid DS, McCollum AM. A tale of two viruses: coinfections of monkeypox and varicella zoster virus in the Democratic Republic of Congo. Am J Trop Med Hyg. 2021;104(2):604–611. doi: 10.4269/ajtmh.20-0589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis. 2004;4(1):15–25. doi: 10.1016/S1473-3099(03)00856-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs 2022; [Epub ahead of print] doi:10.1007/s40265-022-01742-y [DOI] [PMC free article] [PubMed]
  • 61.Hoy SM. Tecovirimat: first global approval. Drugs. 2018;78(13):1377–1382. doi: 10.1007/s40265-018-0967-6. [DOI] [PubMed] [Google Scholar]
  • 62.Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, Lovejoy C, Meara I, Long P, Hruby DE. Oral Tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53. doi: 10.1056/NEJMoa1705688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Alvarez-Cardona JJ, Whited LK, Chemaly RF. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. Future Microbiol. 2020;15(6):389–400. doi: 10.2217/fmb-2019-0288. [DOI] [PubMed] [Google Scholar]
  • 64.Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox. Antiviral Res. 2017;143:269–277. doi: 10.1016/j.antiviral.2017.01.009. [DOI] [PubMed] [Google Scholar]
  • 65.De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci. 2002;23(10):456–458. doi: 10.1016/S0165-6147(02)02091-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Kravcik S. Cidofovir for cytomegalovirus retinitis. Ann Intern Med. 1997;127(6):490–491. doi: 10.7326/0003-4819-127-6-199709150-00015. [DOI] [PubMed] [Google Scholar]
  • 67.Holland GN, Van Natta ML, Goldenberg DT, Ritts R, Jr, Danis RP, Jabs DA, Studies of Ocular Complications of AIDS Research Group Relationship between opacity of cytomegalovirus retinitis lesion borders and severity of immunodeficiency among people with AIDS. Invest Ophthalmol Vis Sci. 2019;60(6):1853–1862. doi: 10.1167/iovs.18-26517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis. 2006;10(3):193–201. doi: 10.1016/j.ijid.2005.12.001. [DOI] [PubMed] [Google Scholar]
  • 69.Hopkins RJ, Kramer WG, Blackwelder WC, Ashtekar M, Hague L, Winker-La Roche SD, Berezuk G, Smith D, Leese PT. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Clin Infect Dis. 2004;39(6):759–766. doi: 10.1086/422998. [DOI] [PubMed] [Google Scholar]
  • 70.Petersen BW, Damon IK, Pertowski CA, Meaney-Delman D, Guarnizo JT, Beigi RH, Edwards KM, Fisher MC, Frey SE, Lynfield R, Willoughby RE. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep. 2015;64(RR-02):1–26. [PubMed] [Google Scholar]
  • 71.Gilbert SC. Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine. 2013;31(39):4241–4246. doi: 10.1016/j.vaccine.2013.03.020. [DOI] [PubMed] [Google Scholar]
  • 72.Overton ET, Lawrence SJ, Stapleton JT, Weidenthaler H, Schmidt D, Koenen B, Silbernagl G, Nopora K, Chaplin P. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine. 2020;38(11):2600–2607. doi: 10.1016/j.vaccine.2020.01.058. [DOI] [PubMed] [Google Scholar]
  • 73.Volz A, Sutter G. Modified Vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res. 2017;97:187–243. doi: 10.1016/bs.aivir.2016.07.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs. 2008;17(4):555–564. doi: 10.1517/13543784.17.4.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Russell PK. Vaccines in civilian defense against bioterrorism. Emerg Infect Dis. 1999;5(4):531–533. doi: 10.3201/eid0504.990413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, Yoder SM, Rock MT, Crowe JE, Jr, Edwards KM. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA. 2004;292(10):1205–1212. doi: 10.1001/jama.292.10.1205. [DOI] [PubMed] [Google Scholar]
  • 77.Hou J, Wang S, Li D, Carpp LN, Zhang T, Liu Y, Jia M, Peng H, Liu C, Wu H, Huang Y, Shao Y. Early pro-inflammatory signal and T-cell activation associate with vaccine-induced anti-vaccinia protective neutralizing antibodies. Front Immunol. 2021;12:737487. doi: 10.3389/fimmu.2021.737487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Wen B, Deng Y, Chen H, Guan J, Chuai X, Ruan L, Kong W, Tan W. The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques. Mol Ther. 2013;21(9):1787–1795. doi: 10.1038/mt.2013.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Deng Y, Chuai X, Chen P, Chen H, Wang W, Ruan L, Li W, Tan W. Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques. Vaccine. 2017;35(25):3347–3353. doi: 10.1016/j.vaccine.2017.04.059. [DOI] [PubMed] [Google Scholar]
  • 80.Liu Q, Li Y, Luo Z, Yang G, Liu Y, Liu Y, Sun M, Dai J, Li Q, Qin C, Shao Y. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. AIDS. 2015;29(6):649–658. doi: 10.1097/QAD.0000000000000595. [DOI] [PubMed] [Google Scholar]
  • 81.Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C, Petersen B, Challberg M. The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antiviral Res. 2019;168:168–174. doi: 10.1016/j.antiviral.2019.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Russo AT, Berhanu A, Bigger CB, Prigge J, Silvera PM, Grosenbach DW, Hruby D. Co-administration of tecovirimat and ACAM2000™ in non-human primates: effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine. 2020;38(3):644–654. doi: 10.1016/j.vaccine.2019.10.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Russo AT, Grosenbach DW, Brasel TL, Baker RO, Cawthon AG, Reynolds E, Bailey T, Kuehl PJ, Sugita V, Agans K, Hruby DE. Effects of treatment delay on efficacy of Tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. J Infect Dis. 2018;218(9):1490–1499. doi: 10.1093/infdis/jiy326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrob Agents Chemother. 2015;59(7):4296–4300. doi: 10.1128/AAC.00208-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Whitehouse ER, Rao AK, Yu YC, Yu PA, Griffin M, Gorman S, Angel KA, McDonald EC, Manlutac AL, de Perio MA, McCollum AM, Davidson W, Wilkins K, Ortega E, Satheshkumar PS, Townsend MB, Isakari M, Petersen BW. Novel treatment of a vaccinia virus infection from an occupational needlestick—San Diego, California, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(42):943–946. doi: 10.15585/mmwr.mm6842a2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, Lovejoy C, Meara I, Long P, Hruby DE. Oral Tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53. doi: 10.1056/NEJMoa1705688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004;428(6979):182–185. doi: 10.1038/nature02331. [DOI] [PubMed] [Google Scholar]
  • 88.Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L, Jr, Spano YE, Silvera PM, Moss B. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci USA. 2008;105(31):10889–10894. doi: 10.1073/pnas.0804985105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FHM, Niesters HGM, van Doornum G, van der Zeijst BAM, Mateo L, Chaplin PJ, Osterhaus ADME. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol. 2005;79(12):7845–7851. doi: 10.1128/JVI.79.12.7845-7851.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis. 2004;38(12):1749–1753. doi: 10.1086/421266. [DOI] [PubMed] [Google Scholar]
  • 91.Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine. 2007;25(1):34–42. doi: 10.1016/j.vaccine.2006.07.022. [DOI] [PubMed] [Google Scholar]
  • 92.Overton ET, Lawrence SJ, Wagner E, Nopora K, Rösch S, Young P, Schmidt D, Kreusel C, De Carli S, Meyer TP, Weidenthaler H, Samy N, Chaplin P. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial. PLoS One. 2018;13(4):e0195897. doi: 10.1371/journal.pone.0195897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P. A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56–80-year-old subjects. PLoS One. 2016;11(6):e0157335. doi: 10.1371/journal.pone.0157335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Brown K, Leggat PA. Human monkeypox: current state of knowledge and implications for the future. Trop Med Infect Dis. 2016;1(1):8. doi: 10.3390/tropicalmed1010008. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers of Medicine are provided here courtesy of Nature Publishing Group

RESOURCES